New review challenges plant-based omega-3 assumptions

A new peer-reviewed review by Patrick Hanaway, MD argues that plant-derived omega-3s may be more clinically useful than long-held nutrition dogma suggests. The article could influence how clinicians think about omega-3 recommendations for vegans, vegetarians and patients with low intake.

Why it matters: - The review challenges a core assumption in nutrition: that plant-based omega-3s are too inefficient to matter clinically. - The findings could expand treatment options for clinicians advising patients with low omega-3 intake, especially vegans and vegetarians. - The paper also points to a more diverse supply strategy at a time when marine omega-3 demand is rising and global intake remains below recommended levels for most people.

What happened: - Patrick Hanaway, MD published a peer-reviewed review article in Integrative and Complementary Therapies. - The review synthesizes more than 120 peer-reviewed studies on plant-based omega-3 metabolism and clinical outcomes. - Hanaway argues that newer evidence changes how healthcare practitioners should evaluate plant-derived omega-3s. - The article frames the work as a possible shift in clinical thinking for physicians, dietitians, nutritionists and other healthcare practitioners.

The details: - The review says conventional blood DHA measurements may miss how the body produces, stores and uses EPA and DHA across tissues. - Newer analytical techniques can track omega-3 activity in the liver, brain and adipose tissue. - The paper highlights stearidonic acid, or SDA, a plant-derived omega-3 found in high concentrations in Buglossoides arvensis seed oil, commercially known as Ahiflower®. - Hanaway says SDA may contribute clinically meaningful benefits through pathways different from standard EPA and DHA supplementation. - The review cites human and preclinical studies showing effects on gut microbiome balance, gut barrier integrity, inflammatory signaling, insulin sensitivity, hormonal balance and metabolic health. - Hanaway also provides practical therapeutic guidance, including dosing recommendations for adults and children and considerations for inflammatory conditions, metabolic health and general wellness. - The review places emphasis on Ahiflower® oil because it is a rich source of SDA, which bypasses the body's main rate-limiting conversion step from alpha-linolenic acid, or ALA. - Natures Crops International said the publication supports a broader view of how different omega-3 sources can work together. - Hanaway said the findings show a bigger view of omega-3 intake, metabolism and storage beyond blood-based measures, and said the point is especially notable for vegans and vegetarians who do not consume EPA or DHA without supplementation.

Between the lines: - The review does not reject marine omega-3s; it argues for a complementary model that treats plant and marine sources as part of a broader nutrition strategy. - The shift in emphasis from blood markers to tissue-level metabolism could change how researchers define omega-3 status and how clinicians judge effectiveness. - The focus on SDA also gives plant-based omega-3 products a more specific scientific footing than a general appeal to “plant-based” nutrition.

What's next: - Clinicians may begin using the review as a reference when advising patients on omega-3 intake. - The paper could intensify debate over whether current omega-3 testing and dietary guidance rely too heavily on blood DHA alone. - Brands and ingredient suppliers may use the review to support product positioning around SDA and complementary omega-3 strategies.

The bottom line: - Hanaway’s review argues that plant-based omega-3s deserve a larger role in clinical nutrition, not as substitutes for marine sources, but as part of a more complete framework for omega-3 health.